Cite
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
MLA
Hueber, Wolfgang, et al. “Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn’s Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial.” Gut, vol. 61, no. 12, Dec. 2012, pp. 1692–700. EBSCOhost, https://doi.org/10.1136/gutjnl-2011-301668.
APA
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., & Travis, S. P. L. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 61(12), 1692–1700. https://doi.org/10.1136/gutjnl-2011-301668
Chicago
Hueber, Wolfgang, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D. R Higgins, Jan Wehkamp, et al. 2012. “Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn’s Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial.” Gut 61 (12): 1692–1700. doi:10.1136/gutjnl-2011-301668.